

Mounjaro is a once-weekly prescription injection containing tirzepatide, used in Singapore for medical weight management and type 2 diabetes treatment. It is a dual-hormone GLP-1 + GIP receptor agonist, making it more advanced than older GLP-1-only medications like semaglutide (Ozempic/Wegovy). By acting on two metabolic pathways, it provides stronger appetite suppression, improved blood sugar control, and greater overall weight loss results.


Tirzepatide is generally considered for patients with a body mass index (BMI) of 30 or higher. It may also be prescribed for patients with a BMI of 27 or higher if they have weight-related conditions such as type 2 diabetes, high blood pressure, or elevated cholesterol. These guidelines are consistent with international standards for prescription weight loss medications.
This treatment is often recommended for patients who require greater weight reduction than what single-pathway GLP-1 injections typically achieve. It may be suitable for individuals who:
Tirzepatide is not suitable for everyone. It should not be used by:
Each patient undergoes a full consultation before starting tirzepatide. Dr Edwin and our doctors review medical history, BMI, lifestyle, and treatment goals to ensure suitability. Ongoing monitoring helps adjust doses, manage side effects, and track progress for safe and effective outcomes.

The duration of each pen varies depending on the weekly dose:
This means the monthly cost of tirzepatide may range significantly depending on the prescribed dose and treatment plan.

Several factors determine the overall cost of treatment, including:

















